Ozempic vs. Wegovy: The Real Difference (and the Real Price)

What's actually different between Ozempic and Wegovy?

Google either name and the other one shows up in the autocomplete — for good reason, because they're built from the exact same molecule. Ozempic and Wegovy are both semaglutide, made by the same company, Novo Nordisk, using the same manufacturing process. They are not two competing drugs from rival companies fighting for the same patient. They're closer to two editions of one product, sold under different names because they're approved to treat two different things.

Three things genuinely separate them, and everything else — the price you pay, whether insurance covers it, whether a savings card applies — flows downstream from these three facts rather than from the molecule itself.

• FDA-approved use: Ozempic is approved only for type 2 diabetes. Wegovy is approved for chronic weight management, and since 2024 also for reducing cardiovascular risk in adults with established heart disease and overweight or obesity.
• Dose ceiling: Ozempic's approved maximum is 2mg weekly. Wegovy's standard ceiling is 2.4mg, and a newer higher-dose version, Wegovy HD, reaches 7.2mg for patients who need more — a strength Ozempic doesn't offer at any price.
• What follows the label: because these are legally two different approved products, insurance formularies, manufacturer savings cards, and Medicare rules all treat them differently, even though the syringe — or the new pill — contains the identical active ingredient.

Which one am I actually supposed to get — diabetes or weight loss?

The honest answer is that your diagnosis decides this before your preference does. If you have type 2 diabetes, Ozempic is the on-label choice, and it's the one your insurance is built to cover. If your goal is weight management — whether or not you also have diabetes — Wegovy is the drug that actually carries that FDA approval, based on a BMI of 30 or higher, or 27 or higher with a weight-related condition like high blood pressure or sleep apnea. Wegovy also covers a second, separate use: reducing cardiovascular events in adults who already have heart disease and are overweight or living with obesity, based on the SELECT trial.

Both drugs are now available beyond the weekly injection, too. Novo Nordisk added an Ozempic-branded tablet for type 2 diabetes, and separately, Wegovy launched as a once-daily pill at US pharmacies in January 2026 — the first oral GLP-1 approved specifically for weight management. If needles are the real obstacle, Wegovy pills and patches walks through how the oral version compares to the injection on its own terms.

A prescriber can still write either drug off-label — Ozempic for weight loss without a diabetes diagnosis, or in rarer cases Wegovy for someone who technically doesn't meet its BMI threshold. That's legal and it happens. What it doesn't do is change how your insurance company reads the prescription, which is where the next few sections matter more than the molecule itself.

Does Wegovy work better for weight loss than Ozempic?

There's no trial that pitted brand-name Ozempic against brand-name Wegovy head-to-head, because there's no clinical reason to run one — they're the same drug. The real comparison is dose against dose. Wegovy's approval rests on the STEP program, and STEP 1 specifically found that adults taking the full 2.4mg dose lost close to 15% of their body weight on average over 68 weeks, against roughly 2% on placebo. A newer, higher 7.2mg version, Wegovy HD, approved in March 2026 on the strength of the STEP UP trial, pushed the average further still — into the low twenties as a percentage of starting body weight.

Ozempic never gets tested at that dose, because 2mg is its approved ceiling — noticeably below Wegovy's 2.4mg standard dose, let alone the HD strength. Real-world studies of people using Ozempic off-label for weight loss, capped at that lower dose, consistently report smaller average results than the STEP trials' findings at 2.4mg. So the fair way to frame this isn't "Wegovy is a stronger drug" — it's that Wegovy is semaglutide dosed at the level the weight-loss trials actually tested, and Ozempic, used for that purpose, generally isn't.

Which costs less — Ozempic or Wegovy?

This depends entirely on which pathway you're comparing, and the two brands trade the lead depending on the tier. The table above lines up every pathway we verified side by side; here's what's actually behind the numbers.

Compounded semaglutide

Since compounded semaglutide isn't sold under either brand name, there's no Ozempic-versus-Wegovy split here — one compounded product serves both use cases. Fridays holds the lowest verified price, $150 to $249 a month depending on plan length, with medication, consult, and shipping bundled and no separate membership fee. Mochi Health prices it in two transparent pieces: a $79 monthly membership plus $99 for the medication itself at any dose, for $178 a month flat. Neither is FDA-approved Ozempic or Wegovy — both are dispensed under a narrower 503A individual-patient compounding pathway now that semaglutide's FDA shortage designation has been resolved.

Brand self-pay, no insurance

Here's where it gets genuinely close, because Novo Nordisk built nearly parallel self-pay ladders for both drugs. Both injections start at the same intro price for the first two fills, then step up to a maintenance-dose price that runs slightly higher for Ozempic than for Wegovy, since Ozempic's ceiling dose costs more than its mid-range one — the exact tiers are in the table above.

The oral tablets follow a similar shape: both start at the same low entry price, then Ozempic's version climbs further at its top dose than Wegovy's does.

Retail list price without any program tells a different story, and it's the one place the two brands genuinely diverge: Wegovy runs meaningfully higher than Ozempic — a gap that mostly disappears once either self-pay program is applied.

With insurance and the manufacturer savings card

This is the tier where the label really shows up. Both cards can bring your cost down to $25 a month — but the eligibility rules are asymmetric. Ozempic's savings card requires commercial insurance that covers Ozempic and a prescription matching its type-2-diabetes label specifically; a chart that says "weight loss" doesn't qualify, even if you happen to have insurance. Wegovy's card only asks that your plan cover Wegovy for weight management, which is its actual approved use — so a weight-loss diagnosis alone is enough. In practice, that means a woman using semaglutide for weight loss without a diabetes diagnosis has a real shot at Wegovy's $25 tier and effectively none at Ozempic's, no matter how good her insurance otherwise is.

Can my doctor just prescribe Ozempic instead of Wegovy to save money?

Yes, and it's a common enough workaround that it's worth understanding what it actually buys you. A provider can legally write an Ozempic prescription for weight loss, and because Ozempic's list price and self-pay ladder tend to run a bit lower than Wegovy's, some women land on this route purely to save money. It can work at the self-pay tier — $349 to $499 a month for the pen isn't nothing, but it's less than Wegovy's uninsured retail price.

What it doesn't do is unlock Ozempic's $25 savings card or improve your odds with insurance, because both are gated to the type-2-diabetes label. A weight-loss-only prescription for Ozempic generally gets denied by insurance the same way a weight-loss-only prescription for any diabetes drug does, and the savings card requires that same label match. Medicare is stricter still: federal law bars Part D from covering any drug prescribed solely for weight loss, so this workaround doesn't help there either. If cost is genuinely the driver and you don't have a diabetes diagnosis, it's worth pricing out Ozempic self-pay against Wegovy's insured tier before assuming the diabetes drug is automatically cheaper — for many women with a weight-management insurance benefit, it isn't.

Can you switch between Ozempic and Wegovy?

Yes, and it's a routine clinical change rather than a complicated one — because the two drugs share an active ingredient, there's no dose-conversion math the way there is between genuinely different molecules. Prescribers move patients between them for a few common reasons: an insurance formulary shifts to favor one brand, a diagnosis changes (a prediabetes finding turns into a formal type 2 diagnosis, for instance), or someone on Ozempic off-label wants access to Wegovy's higher dose ceiling once they've plateaued. Whichever direction you're headed, your prescriber typically starts you on the new brand's own titration schedule rather than jumping straight to a maintenance dose — the timing specifics are worth discussing directly with whoever is writing the prescription.

How do Ozempic and Wegovy stack up against Mounjaro and Zepbound?

Mounjaro and Zepbound are a different molecule entirely — tirzepatide, made by Eli Lilly, not Novo Nordisk — but they follow the exact same diabetes-versus-weight-loss split as this comparison: Mounjaro for type 2 diabetes, Zepbound for chronic weight management. In the one trial that tested tirzepatide against semaglutide head-to-head, SURMOUNT-5, tirzepatide produced a bigger average weight loss than semaglutide at matching top doses. That comparison, including current Mounjaro and Zepbound pricing, is covered in full on Mounjaro vs. Ozempic, Wegovy vs. Mounjaro, and Wegovy vs. Zepbound — this page stays focused on the Novo Nordisk side of the decision rather than re-covering that ground.

Are the side effects different between Ozempic and Wegovy?

Not in kind — both cause the same family of gastrointestinal side effects, because that's the mechanism, not a side issue of it. Nausea, vomiting, diarrhea, and constipation are the most commonly reported problems with either drug, usually clustering hardest in the weeks right after a dose increase before easing.

What can differ is intensity, and that tracks with dose more than with brand name. Wegovy's higher approved ceiling — and especially the newer 7.2mg HD strength — means some women notice more GI symptoms at Wegovy's top dose than they did at Ozempic's lower 2mg cap, simply because a bigger dose of the same molecule tends to produce a bigger effect across the board, side effects included. That's a reason to titrate carefully regardless of which brand you're on, not a reason to assume one name is inherently gentler than the other.

Does either make more sense for perimenopause or menopause weight gain?

The weight shift that shows up in perimenopause has a specific hormonal driver: falling estrogen worsens insulin resistance and pushes fat storage toward the abdomen, on top of whatever else is going on in a woman's life at 40-plus. Because Ozempic and Wegovy are the same molecule, both act on that same underlying pathway — improving insulin sensitivity and quieting appetite signaling — which is part of why GLP-1 medications generally come up so often in this stage of life, independent of which brand name is on the box.

Where the dose ceiling might matter more here than in a younger population is worth naming plainly: if weight, not glucose control, is genuinely the primary target — which is true for a lot of women navigating midlife weight gain without a diabetes diagnosis — Wegovy's higher approved dose gives it more room to work with than Ozempic's 2mg cap allows. No trial has isolated a perimenopausal or postmenopausal subgroup for either drug specifically, so there's no menopause-specific verdict to report beyond that general pattern. For most women in this stage, the more useful question usually isn't Ozempic versus Wegovy as brand names at all — it's whether the on-label weight-management option fits their diagnosis, insurance, and budget better than the diabetes-branded drug used off-label, which is exactly the asymmetry this whole comparison keeps coming back to.

Which one is right for you? Verdict by profile

• You have a type 2 diabetes diagnosis: Ozempic is the on-label choice, and it's the one your insurance and the NovoCare Savings Card are actually built to cover at $25/mo.
• Weight loss is your goal and you have insurance with a weight-management benefit: Wegovy is the one that can reach $25/mo off that diagnosis alone — Ozempic's savings card can't, no matter how good the rest of your coverage is.
• You want the strongest evidence for average weight loss and cost is secondary: Wegovy, dosed at 2.4mg or the newer 7.2mg HD strength, is the version of this molecule actually tested at that level in the STEP trials.
• You're paying cash and budget is the deciding factor: compounded semaglutide beats every brand option for either use case, running well below either NovoCare self-pay ladder.
• You don't have a diabetes diagnosis but want the cheaper self-pay sticker price: Ozempic's pen and pill self-pay tiers run slightly lower than Wegovy's uninsured retail price — just don't expect that to translate into savings-card or insurance eligibility.
• Needles are a hard no: both now come in a once-daily pill — the Ozempic tablet for a diabetes diagnosis, the Wegovy pill for weight management — see Wegovy pills and patches for how the oral route compares to the injection.